KRChoksey: Gland Pharma IPO - Investment Rationale
Tablets sits before packaging at a drug manufacturing unit in Kursk, Russia. (Photographer: Andrey Rudakov/Bloomberg)

KRChoksey: Gland Pharma IPO - Investment Rationale

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

KRChoksey Report

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small-volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets.

The company operates primarily under a business to business model and have an excellent track record in the development, manufacturing, and marketing of complex injectables.

This presence across the value chain has helped the company to witness the exponential growth.

Click on the attachment to read the full report:

KRChoksey Gland Pharma IPO Note.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Also read: Gland Pharma IPO: All You Need To Know

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.